Cite
HARVARD Citation
Penn-Nicholson, A. et al. (2018). Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet. 6 (4), pp. 287-298. [Online].